Skip to main content
. Author manuscript; available in PMC: 2019 May 20.
Published in final edited form as: Mol Pharm. 2018 Apr 4;15(5):1778–1790. doi: 10.1021/acs.molpharmaceut.7b01024

Figure 5.

Figure 5

Enzalutamide-encapsulated–anti-PSMA conjugates of hybrid nanoparticles efficiently control cell cycle and repress AR target gene expression. (A–C) Graphic representation of BrdU analysis in LNCaP, MCF7, and PC3 cells in response to vehicle, enzalutamide, NP, NP +MDV3100, enzalutamide-loaded nanoparticle, nanoparticle with anti-PSMA, or enzalutamide-loaded nanoparticle coated with anti-PSMA. (D–F) Graphic representation of KLK3 mRNA (PSA) analysis in LNCaP, MCF7, and PC3 cells exposed to vehicle, enzalutamide, NP, NP+MDV3100, enzalutamide-loaded nanoparticle, nanoparticle with anti-PSMA, or enzalutamide-loaded nanoparticle coated with anti-PSMA. For these experiments, 5 μM enzalutamide was used. Each data point is a mean ± SD from three or more independent experiments. ★p and ★★p < 0.05 were considered as statistically significant. Note: treated with drugs for 48 h and BrdU pulsed for last 2 h with drug for cell cycle analysis.